UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 26, 2010
Idenix Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 000-49839 | 45-0478605 | ||
(State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
60 Hampshire Street Cambridge, MA | 02139 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:617-995-9800
(Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
(d) | Exhibits | ||
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: | |||
99.1 | Press Release, “Idenix Pharmaceuticals Reports Second Quarter and Six Month 2010 Financial Results and Provides Research and Development Update” dated July 26, 2010. |
Idenix Pharmaceuticals, Inc. | ||||
Date: July 26, 2010 | By: | /s/ Ronald C. Renaud, Jr. | ||
Ronald C. Renaud, Jr. | ||||
Chief Financial Officer |
Exhibit No. | Description | |
99.1 | “Idenix Pharmaceuticals Reports Second Quarter 2010 Financial Results and Provides Research and Development Update on HCV Programs” dated July 26, 2010. |